The FDA's Approval of Gazyva for Follicular Lymphoma
Now what?
We've presented just a brief overview of findings from the recent GALLIUM study and related online sources.
There are many intricacies in the treatment protocol to be considered, along with some ambiguities regarding research findings.
The best source of information regarding treatment regimens is, as always, your oncologist and healthcare team.
When speaking with them, be sure to ask any questions you may have.
Freely discuss the ‘risks vs. benefits’ regarding bendamustine.
Make sure you understand the options open to you, as your oncologist and you, together, choose the treatment modality that best fits your treatment needs.
References
http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=6300155
https://www.lymphomas.org.uk/about-lymphoma/types/non-Hodgkin-lymphoma/follicular-lymphoma
https://www.curetoday.com/articles/fda-approves-gazyva-for-advanced-follicular-lymphoma
https://www.gene.com/media/press-releases/14618/2016-02-26/fda-approves-genentechs-gazyva-obinutuzu
http://www.rituxan.com/hem/patient/what-is-rituxan
https://www.lymphomas.org.uk/about-lymphoma/types/non-Hodgkin-lymphoma/follicular-lymphoma#stage
https://www.iodine.com/compare/gazyva-vs-rituxan
https://www.uptodate.com/contents/anaphylaxis-symptoms-and-diagnosis-beyond-the-basics
https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/monoclonal-antibody/art-20047808
https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/what-is-non-hodgkin-lymphoma.html
https://www.medscape.com/viewarticle/873442
https://www.medscape.com/viewarticle/886549
https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm488013.htm
https://www.healio.com/hematology-oncology/lymphoma/news/in-the-journals
